Table 6.
Summary of defined alignment borders
| DMT | Jack DL, Yang NM, Saier MH, Jr. (2001) | Pfam architecture | Frequency of architecture | New TM structure |
|---|---|---|---|---|
| Cation efflux | N/A | 4-LC-2 | 96% | 4+2 |
| EamA | N/A | 5+5 | 44% | 5+5 |
| DUF803 | N/A | (1)+4 | 80% | 4+5 |
| DUF914 | N/A | 7+0 | 88% | 5+5 |
| DUF1632 | 9-10 TM | 5+(3) | 80% | 5+5 |
| NST | 10 TM | (2)+6 | 97% | 5+5 |
| TPT | 6-9 TM | (EamA)+4 | 77% | 0+5 |
| UAA | 10 TM | 3-LC-1-LC-5 | 93% | 5+5 |
| UPF0546 | N/A | 2+0 | 96% | 4+0 |
| Zip | N/A | 2-LC-1-LC-1-2 | 93% | 3+5 |
This table lists for human DMT families from [additional file 2: supplementary table S2], the evidence provided by Jack DL, Yang NM, Saier MH, Jr. (2001), and the Pfam dominant architecture and prevalence, and the TM structure recommended using evidence type from [additional file 5: supplementary table S4]. The parentheses in the Pfam architecture column indicate TMs or unrelated domains not covered by the Pfam-A hit to the current DMT.